New hope for Hard-to-Treat anal and rectal cancers
NCT ID NCT07511023
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called sacituzumab tirumotecan in 20 people with advanced anal or rectal cancer that has spread or cannot be removed and has not responded to other treatments. The goal is to see if the drug can shrink tumors and how safe it is. Participants will receive the drug and be monitored for side effects and tumor response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CELL CARCINOMA OF THE ANUS/ RECTUM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood tests may guide breast cancer treatment before surgery
- New drug IDP-001 takes on advanced cancers in early trial
- New liposomal drug takes on advanced cancers
- Blood test could guide anal cancer treatment, reducing side effects
- Experimental drug targets Hard-to-Treat cancers, but trial ends early
- Radiation boosts cancer drug in Tough-to-Treat myeloma